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Background: Minimally invasive endothermal techniques, for example, radiofrequency ablation (RFA), have
revolutionized the treatment of insufficient truncal veins and are associated with an excellent outcome. The use of
thermal energy requires the instillation of tumescent anesthesia around the vein. Mechanochemical endovenous
ablation (MOCA™) combines mechanical endothelial damage, using a rotating wire, with simultaneous infusion of a
liquid sclerosans. Tumescent anesthesia is not required as no heat is used. Prospective studies using MOCA™ in
both great and small saphenous veins showed good anatomical and clinical results with fast postoperative
recovery.
Methods/Design: The MESSI trial (Mechanochemical Endovenous ablation versus radiofrequency ablation in the
treatment of primary Small Saphenous vein Insufficiency) is a multicenter randomized controlled trial in which a
total of 160 patients will be randomized (1:1) to MOCA™ or RFA. Consecutive patients with primary small saphenous
vein incompetence, who meet the eligibility criteria, will be invited to participate in this trial. The primary endpoint
is anatomic success, defined as occlusion of the treated veins objectified with duplex ultrasonography at 1 year
follow-up. Secondary endpoints are post-procedural pain, initial technical success, clinical success, complications
and the duration of the procedure. Initial technical success is defined as the ability to position the device
adequately, treat the veins as planned and occlude the treated vein directly after the procedure has been proven
by duplex ultrasonography. Clinical success is defined as an objective improvement of clinical outcome after
treatment, measured with the Venous Clinical Severity Score (VCSS). Power analyses are conducted for anatomical
success and post-procedural pain.
Both groups will be evaluated on an intention-to-treat principle.
Discussion: The hypothesis of the MESSI trial is that the anatomic success rate of MOCA™ is not inferior to RFA.
The second hypothesis is that post-procedural pain is significantly less after MOCA compared to RFA.
Trial registration: Trial registration: NTR4613 Date of trial registration: 28 May 2014.
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Varicose veins are common and symptoms range from
cosmetic complaints to venous ulcers. The incidence in-
creases with age and women are more affected than men.
The majority of venous associated complaints are due to
great saphenous vein (GSV) insufficiency; however, in 15%
of patients, small saphenous vein (SSV) insufficiency is the
main cause [1-3].
During the last decade, minimally invasive endothermal
catheter modalities took over the role of surgical therapy in
the treatment of small saphenous insufficiency. Surgery has
been associated with high recurrence rates (25 to 60%),
nerve injuries, and significant postoperative complications
[4-10]. Success rates after endothermal catheter techniques,
for example, endovenous laser ablation (EVLA) and radio-
frequency ablation (RFA), are excellent. At 1 year follow-
up, the anatomical success rate of RFA is 88% [10]. RFA is
associated with fewer procedure-related symptoms, super-
ior cosmetic results and earlier resumptions of daily activity
compared to traditional surgical procedures [11,12]. How-
ever, to perform endothermal techniques, tumescent anes-
thesia is essential. Furthermore, heat-induced nerve injury
and post-procedural pain is inherent to endothermal abla-
tion and can become chronic. Nerve injuries after endo-
thermal ablation of SSV are seen in up to 11% [13].
Mechanochemical endovenous ablation (MOCA™), using
the ClariVein™ system (Vascular Insights LLC, Madison,
CT, USA) was introduced in Europe in 2010. Mechanical
injury to the endothelium by a rotating wire at the tip of a
catheter is combined with an infusion of liquid sclerosans,
without the use of tumescent anesthesia. In Europe, the
ClariVein™ device was registered on April 26, 2010, CE
558723.
Recently, the authors published the first results of
MOCA™ in SSV. Occlusion rates in 50 patients were 100%
at 6 weeks follow-up and up to 97% at 1 year. In this co-
hort of SSVs, no major complications, including nerve in-
jury, were seen. Minor complications, such as localized
ecchymoses and superficial thrombophlebitis were seen in
12 to 14%. The Venous Clinical Severity Score (VCSS), an
objective measure for varicose vein-specific symptoms,
improved significantly from 3 (IQR 2 to 5) before treat-
ment to 1 (IQR 1 to 3, P <0.001) at 6 weeks follow-up.
Clinical results were retained at 1 year after treatment
(VCSS 1, IQR 1 to 2, P <0.001). Patients were satisfied
after treatment [14]. Several other studies reported prom-
ising data on feasibility, safety, anatomical and clinical suc-
cess regarding MOCA treatment in GSV insufficiency,
without major complications [15-17].
Method/Design
Study design
The multicenter randomized clinical MESSI trial is de-
signed to compare MOCA™ and RFA in the treatmentof SSV insufficiency. Patients with primary SSV insuf-
ficiency, meeting eligibility criteria, will be included at
the outpatient clinics of the participating hospitals after
giving written informed consent. The procedures are
performed or supervised by dedicated vascular surgeons,
who have performed over 20 procedures of both treat-
ment modalities.
The following Dutch vascular centers are participating
in the MESSI trial: St. Antonius Hospital Nieuwegein,
Rijnstate Hospital Arnhem and Rode Kruis Hospital
Beverwijk.
Study objectives
The aim of the study is to show that MOCA™ has no
inferior anatomical success compared to RFA at 1 year
follow-up. The secondary aim is to evaluate post-
procedural pain, which is hypothesized to be signifi-
cantly less after MOCA™.
Sample size calculation
Power analysis is calculated for anatomical success at
1 year follow-up after endovenous treatment of the SSV.
The calculation is based on the hypothesis that MOCA™
will have no inferior occlusion rates at 1 year after treat-
ment compared to RFA. The meta-analysis by Van de Bos
et al. showed anatomical success rates of 88% after RFA
[10]. Our recent study on MOCA™ in SSV showed an oc-
clusion rate of 97% in the group treated according to our
current study protocol [17]. A Chi-square test with a one-
sided 0.05 significance has a power of 80% to observe no
difference between both groups, when each group consists
of 74 patients (non-inferiority principle, range 2%). The
study population of both groups will consist of 148 pa-
tients. Corrected for 7.5% lost to follow-up, the total study
population will consist of 160 patients.
Pain is an important secondary outcome parameter. A
sample size calculation is also performed for this end-
point based on the hypothesis that MOCA™ will have
lower post-procedural pain scores, as measured by a 100-
point pain score, during the first two weeks after surgery.
To evaluate a 30 percent reduction in post-procedural
pain, 58 patients per group are needed (alpha 5%, power
80%). This analysis will be performed after inclusion and
randomization of at least 58 patients in each group.
Primary endpoints
The primary endpoint is anatomic success after treat-
ment of SSV insufficiency with MOCA™ or RFA at 1 year
follow-up. Anatomic success is defined as occlusion of the
treated vein and proven with duplex ultrasonography.
Secondary endpoints
Post-procedural pain is evaluated using a 100-millimeter
visual analog scale (VAS) during the first 2 weeks after
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nical success, clinical success, pain during treatment, com-
plications and duration of the procedure. Initial technical
success is defined as the ability to position the device
adequately, treat the veins as planned and occlude the
treated vein directly after the procedure proven by duplex
ultrasonography. Clinical success is measured using the
Venous Clinical Severity Score (VCSS). Complications re-
lated to the endovenous treatment, that occur within
30 days after treatment, are divided between major com-
plications (deep venous thrombosis, pulmonary embolism,
nerve injury, skin burn), minor complications (ecchy-
mosis, superficial thrombophlebitis, hyperpigmentation,
wound infection, prolonged pain >1 week) and sclerosans-
related complications. Additionally, all endpoints will be
evaluated at 2 and 5 years post-treatment.
Ethical considerations
A patient, who meets the inclusion criteria, will be fully
informed about the trial and provided with a patient in-
formation and informed consent form. Patients willing
to participate in the study are included after signing the
informed consent form. This study is conducted in ac-
cordance with the principles of the Declaration of Helsinki
and Good Clinical Practice guidelines. The study proto-
col has been approved by the medical ethical committee
in Nieuwegein, (VCMO NL42781.100.13) and the local
institutional board of each participating center (LHC
Rijnstate Arnhem/Commissie Lokale Uitvoerbaarheid
RKZ Beverwijk).
Safety and quality control
Data safety monitoring board
The Data Safety Monitoring Board (DSMB) is composed
of three independent physicians: two vascular surgeons
and one dermatologist. The DSMB will review safety
and provide recommendations regarding the conduct of
the study to the steering committee and to the accre-
dited medical ethical committee (VCMO Nieuwegein)
that approved the study protocol. An interim safety ana-
lysis will be performed after treatment and at the 4-week
follow-up of the first 80 patients.
Adverse and severe adverse events
Adverse events (AE) are defined as any undesirable ex-
perience occurring to a participant during the study,
whether or not considered related to the investigational
device. This definition includes events occurring during
hospital stay and up to 30 days of follow-up. Underlying
disease that was present at the time of enrollment is not
reported as an AE, but any increase in the severity of
the underlying disease will be reported as an AE. All
AEs will be monitored from the time of enrollment
through the 30-day follow-up visit. Adverse events willbe recorded on the case record forms. A description of
the event, including the start date, end date, action
taken, and the outcome will be provided.
A severe adverse event is any event leading to death,
deep venous thrombosis, and neurological complications.
Data on AEs will be reported to the DSMB and to the
accredited medical ethical committee via ‘Toetsingonline’
on the website of the Central Committee on Research in-
volving Human Subjects (CCMO, www.ccmo.nl).
Inclusion criteria
Inclusion criteria are: unilateral primary SSV insuffi-
ciency; C2 to C5 varicose veins; diameter of the SSV at
the saphenopopliteal junction ≥3 or ≤12 millimeter; age
between 18 and 80 years and written informed consent.
Exclusion criteria
Exclusion criteria are: C6 varicose veins; previous sur-
gery or endovenous treatment for insufficient SSV of the
ipsilateral leg; oral anticoagulants; pregnancy or lacta-
tion; previous deep venous thrombosis; immobilization;
contraindication or known allergy for sclerosans; coagula-
tion disorders or an increased risk of thromboembolism;
severe renal insufficiency (eGFR <30 ml/min) and/or se-
vere liver insufficiency (leading to coagulation disorders).
Recruitment
A total of 160 patients with primary SSV insufficiency
will be included in the MESSI trial after signing informed
consent (Figure 1). Before treatment begins, a vascular
surgeon or dedicated physician assistant will perform
a physical examination. The Clinical Etiology Anatomy
Pathophysiology (CEAP) score [18] and VCSS [19] are de-
termined. Insufficiency of the SSV is defined by duplex
ultrasound as a retrograde flow >0.5 seconds after calf
compression while standing [20].
After randomization, the SSV is obliterated in an out-
patient setting according to the following: study arm 1:
radiofrequency ablation (RFA) or study arm 2: mechano-
chemical endovenous ablation (MOCA™).
Randomization
Patients will be randomized directly after inclusion by
the treating vascular surgeon or physician assistant to
one of the treatment arms, using a validated web-based
randomization tool (Research Manager, NOVA Business
Software, Zwolle, The Netherlands). The 1:1 randomi-




During RFA, radiofrequency energy is used to heat the
vein wall of the SSV. The catheter is inserted into the
Figure 1 Flow chart. Legend: This figure illustrates the study
design. A total of 160 patients will be randomized to radiofrequency
ablation or mechanochemical endovenous ablation.
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with collapsing and sealing of the vein as effect. Dur-
ing the MESSI study, all participating centers are using
the VNUS™ ClosureFAST™ catheter (VNUS Medical Tech-
nologies, San Jose, California, USA). The VNUS™ Closure-
FAST™ catheter contains a 7-cm long heating element at
the end of the catheter, used for segmental ablation. Every
7-cm segment is treated during a 20-second treatment
cycle in which a temperature of 120 degrees is maintained.
Only the most proximal segment is treated during the two
cycles [21].
The insufficient SSV is punctured distally under
ultrasound-guidance and a guide wire is inserted. An intro-
ducer sheath is placed over the guide wire. Subsequently,Figure 2 ClariVein™ device. Legend: (a) The ClariVein™ device consists of
protrudes with angulated tip from catheter (CL). Acknowledgement: Figure
Therapy. Copyright 2011. International Society of Endovascular Specialists.the RFA catheter is introduced and positioned approxi-
mately 2 cm distal to the saphenopopliteal junction using
ultrasound guidance. Then, tumescent anesthesia is deliv-
ered along the entire SSV to be treated. The target vein is
compressed circumferentially and positioned at least 1 cm
below the skin, due to the tumescence.Mechanochemical endovenous ablation
The MOCA™ technique has been previously described
[15]. Briefly, the ClariVein™ device is a disposable 2.6 F
single-lumen catheter for infusing liquid sclerosans. A
metal wire, fitted distally with a small ball, runs through
the catheter (Figure 2). The motorized handle unit ro-
tates this wire at 3,000 rpm. The purpose of this wire is
to create intimal injury, to induce vasospasm and dis-
perse the liquid sclerosans.
The ClariVein™ catheter is introduced into the distal
SSV through a 4 F micropuncture sheath. The tip of the
dispersion wire is positioned 1 cm distal to the sapheno-
popliteal junction (SPJ). To induce spasm of the prox-
imal SSV, the rotating wire is activated for 10 seconds.
Then, the activated catheter with rotating tip is steadily
withdrawn at the rate of 1 cm every 7 seconds, simulta-
neously dispersing liquid polidocanol (Aethoxysklerol™,
KreusslerPharma, Wiesbaden, Germany). In the prox-
imal 10 cm of the SSV 2 mL 3% polidocanol is used, the
remaindering insufficient SSV is treated with 1.5% poli-
docanol. The total amount of used liquid sclerosans will
be documented and will not exceed the allowed daily
dose of 2 mg/kg/day.Both treatments
After treatment, both the deep venous system and the
treated SSV are scanned by ultrasound.
A compression stocking (20 to 30 mmHg) will be ap-
plied for 24 hours continuously and for 2 weeks during
the daytime. Patients are asked to resume normal activ-
ities immediately after the procedure. No concomitant
phlebectomy or sclerotherapy are performed during themotor unit (H) and infusion catheter (C). (b) The dispersion tip (T)
1 is reproduced with permission from the Journal of Endovascular
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4 weeks is reported in trial results.
Follow-up
After 4 weeks, 1 year, 2 years and 5 years, patients are
seen at the outpatient clinic to determine the anatomical
and clinical success (Table 1). Ultrasound duplex im-
aging, VCSS, CEAP score and health status is measured
at all aforementioned time points. Ultrasound duplex
imaging is done according to a standardized protocol for
all participating hospitals.
Post-procedural pain is evaluated using a linear VAS
score of 0 to 100 mm during the 2 weeks after treat-
ment. After 4 weeks follow-up, any small branch varicos-
ities may be treated when indicated.
Health status measurement
Health status will be measured according to the following:
1. Short Form-36 (SF-36) is a multidimensional
measurement of general health. It yields eight
domains of functional health and well-being scores.
2. Aberdeen Varicose Vein Questionnaire [22] (AVVQ)
is a validated disease-specific health status
measurement for chronic venous insufficiency
(patient reported outcome).
Both the SF-36 and AVVQ questionnaires are com-
pleted pre-procedural and after 4 weeks, 1 year, 2 years
and 5 years of follow-up.
Data collection and management
All data will be collected at each participating treating
center by case report forms (CRFs). Photocopies of the
CRFs will be sent to the coordinating investigator (DB).












AVVQ, Aberdeen Varicose Vein Questionnaire; CEAP, Clinical Etiology Anatomy Path
Venous Clinical Severity Score.system (Research Manager, NOVA Business Software,
Zwolle, The Netherlands) and controlled by an indepen-
dent monitor. The participating centers will be informed
about the current status of recruitment and adverse events
via a newsletter every month. Additionally, there will be
regular contact between the principle investigator and the
local investigators from the participating centers.Statistical analyses
The study results will be evaluated based on intention-
to-treat analysis. Data concerning the 1, 2, and 5 years
follow-up will be analyzed for both study groups on an
intention-to-treat manner by student t-test (normal distri-
bution) or Mann Whitney U-test (skewed distribution).
To test for normality, the Kolmogorov-Smirnov test will
be used. The Chi-square test will be used for binomial
data. All probability values are two-tailed. P <0.05 will be
considered significant. Obliteration rates will be presented
as Kaplan Meier curves, including censoring in case of
loss to follow-up.
An interim analysis will be performed after treatment
and at 4 weeks follow-up for the first 80 patients to
monitor the progression of the study. Final analysis will
be performed after follow-up of the last patient included
in this study is completed.Publication of data
Data will be published after all patients had a follow-up
period of 1 year, regardless of the outcome of the study.
Separate publication of data on pain, initial technical
success and short-term follow-up can be published earlier.
Long-term results will be published after 2 or 5 years
follow-up. Co-authorship will be assigned according to the
‘Recommendations for the Conduct, Reporting, Editing,
and Publication of Scholarly Work in Medical Journals’Study period
4 wk 1 yr 2 yr 5 yr
X X X X
X X X X
X X X X
X X X X
X
X X X X
X X X X
ophysiology classification; SF-36, Short Form 36-Item Health Survey; VCSS,
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Definitions
Anatomical success is defined as occlusion of the treated
SSV segment, measured with duplex ultrasonography.
Clinical success is defined as the objective improve-
ment of clinical outcome after treatment, measured with
the Venous Clinical Severity Score (VCSS).
Initial technical success is defined as the safe place-
ment of the device at the predefined distance from the
SPJ, treatment of the SSV without technical problems and
occlusion of the treated SSV directly after treatment.
Failure of treatment
Failure of treatment is defined as follows:
1. Type 1 (non-occlusion): the treated vein failed to
occlude initially and never occluded during the
follow-up.
2. Type 2 (recanalisation): the treated vein occluded
directly after treatment, but recanalized, partially
(>10 cm) or completely, at a later time point during
follow-up.
a. Type 2a: recanalization of the entire treated
segment of the vein.
b. Type 2b: partial recanalization (open segment
>10 cm) [24].Post-procedural complications (complications occurring
within 30 days after treatment) are defined as follow:
1. Major complication: deep venous thrombosis,
pulmonary embolism, skin burn, or nerve injury.
2. Minor complication: ecchymosis, superficial
phlebitis, hyperpigmentation, induration, wound
infection of the puncture site, or prolonged
pain >1 week.
3. Sclerosans-related complications.
The duration of procedure includes the time of the
procedure, starting from puncture of the vein to the
extracting of the catheter, skin-to-skin contact.
Discussion
The introduction of minimal invasive endovenous abla-
tion techniques has revolutionized the treatment of saphe-
nous vein insufficiency. Different endothermal techniques
have been introduced and tested in many prospective and
randomized studies. Although most research is performed
in GSVs, limited data on SSV is available. The results of
endothermal techniques have proven to be excellent with
a long-term anatomical success rate over 90%; therefore,
the aim for future studies, especially in SSV, is diminishingheat-related complications, for example, pain and nerve
injury, without compromising anatomical and clinical suc-
cess. Until now the gold standard for the treatment of
SSV insufficiency remains unclear.
This trial is designed to compare the anatomical suc-
cess at 1 year after MOCA™ with RFA.
A secondary aim is to investigate whether MOCA™ is
associated with a significant reduction in post-procedural
pain. A major point of discussion is the choice for RFA
above EVLA techniques. Although the meta-analysis of
Van de Bos et al. showed the superiority of endothermal
ablation (EVLA) in terms of anatomical success at 1 to 5
years follow-up [10], the more recent RCT of Rasmussen
et al. has proven that the results of RFA using the
ClosureFast device are at least similar to EVLT. In
this randomized trial, RFA was associated with signifi-
cantly less post-procedural pain compared to EVLA [24].
Furthermore, an important consideration in choosing
ClosureFast is the uniformity of this technique, while
in the case of ELVA, discussion about different tip designs
and wavelengths might occur.
It has been proven that minimally invasive techniques
will lead to a lower incidence of nerve injury in the SSV
compared to conventional surgery (11% versus 28%).
However, sural nerve injury is still considered a major
and potentially underreported complication [25,26].
Due to the fact that no heat and tumescent is used in
MOCA™, nerve injury after SSV ablation might become
a redundant complication.
In conclusion, the MESSI trial is a multicenter random-
ized controlled trial that aims to show a similar anatom-
ical success of MOCA compared to RFA. Additionally, we
hypothesize that this is accompanied by comparable clin-
ical success and a reduction in post-procedural pain after
MOCA™ compared with RFA.Trial status
The MESSI trial began including participants in the second
quarter of 2014. We expect that inclusion will be com-
pleted in the third quarter of 2015.Abbreviations
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